Stocks
Boston Scientific Financial Statements (BSX) |
||||||||||
| Boston Scientificsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 03.08.2023 | 01.11.2023 | 20.02.2024 | 01.05.2024 | 01.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 3 389 | 3 599 | 3 527 | 3 725 | 3 856 | 14 707 | |||
| Operating Income, bln rub | 552.0 | 514.0 | 693.0 | 584.0 | 693.0 | 2 484 | ||||
| EBITDA, bln rub | ? | 744.0 | 798.0 | 801.0 | 1 016 | 1 001 | 3 616 | |||
| Net profit, bln rub | ? | 314.0 | 270.0 | 504.0 | 505.0 | 492.0 | 1 771 | |||
| OCF, bln rub | ? | 190.0 | 658.0 | 698.0 | 957.0 | 164.0 | 2 477 | |||
| CAPEX, bln rub | ? | 121.0 | 206.0 | 206.0 | 267.0 | 245.0 | 924.0 | |||
| FCF, bln rub | ? | 69.0 | 452.0 | 492.0 | 690.0 | -81.0 | 1 553 | |||
| Dividend payout, bln rub | 14.0 | 14.0 | 0.000 | 0.000 | 0.000 | 14.0 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 4.46% | 5.19% | 0.00% | 0.00% | 0.00% | 0.79% | ||||
| OPEX, bln rub | 1 766 | 1 923 | 1 806 | 1 961 | 1 954 | 7 644 | ||||
| Cost of production, bln rub | 1 040 | 1 070 | 1 112 | 1 147 | 1 209 | 4 538 | ||||
| R&D, bln rub | 337.0 | 359.0 | 356.0 | 363.0 | 366.0 | 1 444 | ||||
| Interest expenses, bln rub | 65.0 | 70.0 | 66.0 | 65.0 | 69.0 | 270.0 | ||||
| Assets, bln rub | 32 892 | 33 601 | 34 043 | 35 136 | 36 669 | 36 669 | ||||
| Net Assets, bln rub | ? | 17 850 | 18 226 | 18 885 | 19 281 | 19 925 | 19 925 | |||
| Debt, bln rub | 9 365 | 9 454 | 9 299 | 9 492 | 11 001 | 11 001 | ||||
| Cash, bln rub | 570.0 | 426.0 | 952.0 | 865.0 | 2 329 | 2 329 | ||||
| Net debt, bln rub | 8 795 | 9 028 | 8 347 | 8 627 | 8 672 | 8 672 | ||||
| Ordinary share price, rub | 50.0 | 54.1 | 52.8 | 57.8 | 68.5 | 52.5 | ||||
| Number of ordinary shares, mln | 1 436 | 1 446 | 1 465 | 1 465 | 1 468 | 1 468 | ||||
| Market cap, bln rub | 71 833 | 78 225 | 77 326 | 84 709 | 100 571 | 77 120 | ||||
| EV, bln rub | ? | 80 628 | 87 253 | 85 673 | 93 336 | 109 243 | 85 792 | |||
| Book value, bln rub | -1 480 | -1 497 | -573 | -1 109 | -273 | -273 | ||||
| EPS, rub | ? | 0.22 | 0.19 | 0.34 | 0.34 | 0.34 | 1.21 | |||
| FCF/share, rub | 0.05 | 0.31 | 0.34 | 0.47 | -0.06 | 1.06 | ||||
| BV/share, rub | -1.03 | -1.04 | -0.39 | -0.76 | -0.19 | -0.19 | ||||
| EBITDA margin, % | ? | 22.0% | 22.2% | 22.7% | 27.3% | 26.0% | 24.6% | |||
| Net margin, % | ? | 9.27% | 7.50% | 14.3% | 13.6% | 12.8% | 12.0% | |||
| FCF yield, % | ? | 1.64% | 1.82% | 2.10% | 2.01% | 1.54% | 2.01% | |||
| ROE, % | ? | 4.97% | 4.93% | 6.50% | 8.26% | 8.89% | 8.89% | |||
| ROA, % | ? | 2.70% | 2.67% | 3.61% | 4.53% | 4.83% | 4.83% | |||
| P/E | ? | 80.9 | 87.1 | 63.0 | 53.2 | 56.8 | 43.5 | |||
| P/FCF | 61.1 | 54.9 | 47.7 | 49.7 | 64.8 | 49.7 | ||||
| P/S | ? | 5.51 | 5.84 | 5.62 | 5.95 | 6.84 | 5.24 | |||
| P/BV | ? | -48.5 | -52.3 | -134.9 | -76.4 | -368.4 | -282.5 | |||
| EV/EBITDA | ? | 27.8 | 29.2 | 27.4 | 27.8 | 30.2 | 23.7 | |||
| Debt/EBITDA | 3.04 | 3.02 | 2.67 | 2.57 | 2.40 | 2.40 | ||||
| R&D/CAPEX, % | 278.5% | 174.3% | 172.8% | 136.0% | 149.4% | 156.3% | ||||
| CAPEX/Revenue, % | 3.57% | 5.72% | 5.84% | 7.17% | 6.35% | 6.28% | ||||
| Boston Scientific shareholders | ||||||||||
